Bioheart acquires rights of Tissue Genesis’ cell technology (PharmaBiz)
Bioheart acquires rights of Tissue Genesis’ cell technology (PharmaBiz)
Bioheart, Inc. has acquired an option to the worldwide exclusive rights to Tissue Genesis, Inc.’s adipose (fat) derived therapeutic cell technology, which is being developed to treat heart attacks and congestive heart failure.